199 related articles for article (PubMed ID: 7270052)
21. Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra.
Cole DG; Growdon JH; DiFiglia M
Exp Neurol; 1993 Apr; 120(2):223-32. PubMed ID: 8491280
[TBL] [Abstract][Full Text] [Related]
22. [Olivo-ponto-cerebellar atrophy with notable changes of the striato-nigral and pyramidal system].
Kuroda S; Chuda M; Ikeda H; Otsuki S; Tateishi J
Rinsho Shinkeigaku; 1977 May; 17(5):336-43. PubMed ID: 560281
[No Abstract] [Full Text] [Related]
23. [Olivo-ponto-cerebellar and striato-nigral atrophy. 3 anatomo-clinical cases. Review of the literature].
Kohler A
Schweiz Arch Neurol Psychiatr (1985); 1986; 137(2):15-42. PubMed ID: 2422747
[TBL] [Abstract][Full Text] [Related]
24. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD
Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242
[TBL] [Abstract][Full Text] [Related]
25. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease.
Fu Y; Ito M; Fujita Y; Ito M; Ichihara M; Masuda A; Suzuki Y; Maesawa S; Kajita Y; Hirayama M; Ohsawa I; Ohta S; Ohno K
Neurosci Lett; 2009 Apr; 453(2):81-5. PubMed ID: 19356598
[TBL] [Abstract][Full Text] [Related]
26. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Fleming SM; Delville Y; Schallert T
Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
[TBL] [Abstract][Full Text] [Related]
27. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
García de Yébenes J; Avila C; Bazán E; García E; Gervás J; Maseda C; Mena M; Muradas V; Ramos JA
Med Clin (Barc); 1982 Apr; 78(7):259-64. PubMed ID: 7087591
[No Abstract] [Full Text] [Related]
28. [Striato-nigral degeneration (SND): a multisystem atrophy?].
Bergmann M; Schmidtke K; Danek A; Gullotta F; Mehraein P
Schweiz Arch Neurol Psychiatr (1985); 1990; 141(5):389-405. PubMed ID: 1701267
[TBL] [Abstract][Full Text] [Related]
29. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
[TBL] [Abstract][Full Text] [Related]
31. Neuropathology of fetal nigral grafts in patients with Parkinson's disease.
Kordower JH; Freeman TB; Olanow CW
Mov Disord; 1998; 13 Suppl 1():88-95. PubMed ID: 9613724
[No Abstract] [Full Text] [Related]
32. Variations in the "on-off" phenomenon.
Duvoisin RC
Adv Neurol; 1974; 5():339-40. PubMed ID: 4440582
[No Abstract] [Full Text] [Related]
33. Striatal calcium channel antagonist receptors in Huntington's disease and Parkinson's disease.
Watson DL; Carpenter CL; Marks SS; Greenberg DA
Ann Neurol; 1988 Mar; 23(3):303-5. PubMed ID: 2967667
[TBL] [Abstract][Full Text] [Related]
34. Cognitive and motor performance in multiple system atrophy and Parkinson's disease compared.
Testa D; Fetoni V; Soliveri P; Musicco M; Palazzini E; Girotti F
Neuropsychologia; 1993 Feb; 31(2):207-10. PubMed ID: 8455789
[TBL] [Abstract][Full Text] [Related]
35. Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcortico-frontal syndrome.
Bédard MA; Pillon B; Dubois B; Duchesne N; Masson H; Agid Y
Brain Cogn; 1999 Jul; 40(2):289-313. PubMed ID: 10413563
[TBL] [Abstract][Full Text] [Related]
36. Striato-pallidonigral degeneration. (A diagnostic dilemma--case report).
Stehbens JA
Dis Nerv Syst; 1972 Jun; 33(6):387-91. PubMed ID: 4149333
[No Abstract] [Full Text] [Related]
37. Mechanism of action of short- and long-term L-DOPA treatment in parkinsonism: role of the surviving nigrostriatal dopaminergic neurons.
Melamed E; Hefti F
Adv Neurol; 1984; 40():149-57. PubMed ID: 6695591
[No Abstract] [Full Text] [Related]
38. [Medicinal treatment of idiopathic Parkinson's disease].
Klockgether T
Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
[TBL] [Abstract][Full Text] [Related]
39. Levodopa induces apoptosis in cultured neuronal cells--a possible accelerator of nigrostriatal degeneration in Parkinson's disease?
Ziv I; Zilkha-Falb R; Offen D; Shirvan A; Barzilai A; Melamed E
Mov Disord; 1997 Jan; 12(1):17-23. PubMed ID: 8990049
[TBL] [Abstract][Full Text] [Related]
40. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
Hironishi M; Miwa H; Kondo T
No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
